Eli Lilly launches oral weight-loss pill Foundayo in UK

Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2 diabetes, making it the first ‌country in Europe ⁠where ⁠the treatment is available.

The pill, known chemically as orforglipron, will ​be available via private prescription after Britain's medicines regulator authorised the drug on ​August 10, making ⁠it the ‌second GLP-1 oral pill to ​be ​cleared in the UK ⁠after Novo Nordisk's Wegovy.

Lilly said it ​was working with England's health cost-effectiveness ​watchdog, the National Institute for Health and Care Excellence (NICE), on a potential roll-out at the state-run National Health Service.


Also read: Paramount-Warner Bros merger: California may seek cable channel divestitures, film studio safeguards

Lilly said Foundayo ‌will likely be priced between £100 and £120, lower than its Mounjaro ​injection's £330 ​for a ⁠month's supply.

Foundayo remains under review in the European Union, while Novo's Wegovy pill has ​won a positive recommendation from the European Medicines Agency, with a final decision from the European Commission pending.